You just read:

Avant Diagnostics Highlights Published Clinical Utility Data for Theralink® mTOR Pathway Activation Data Predicting Tamoxifen® and Other Endocrine Treatment Response in Estrogen Receptor Positive (ER+) Breast Cancer

News provided by

Avant Diagnostics, Inc.

Jul 18, 2017, 07:30 ET